Immuneering Corp (IMRX)
1.59
-0.06
(-3.64%)
USD |
NASDAQ |
May 07, 12:08
Immuneering Price to Book Value: 0.5206 for May 7, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 06, 2024 | 0.5402 |
| May 03, 2024 | 0.5369 |
| May 02, 2024 | 0.5107 |
| May 01, 2024 | 0.5009 |
| April 30, 2024 | 0.4649 |
| April 29, 2024 | 0.4845 |
| April 26, 2024 | 0.4813 |
| April 25, 2024 | 0.4682 |
| April 24, 2024 | 0.4911 |
| April 23, 2024 | 0.5336 |
| April 22, 2024 | 0.5631 |
| April 19, 2024 | 0.5893 |
| April 18, 2024 | 0.5795 |
| April 17, 2024 | 0.6013 |
| April 16, 2024 | 0.5949 |
| April 15, 2024 | 0.6191 |
| April 12, 2024 | 0.6789 |
| April 11, 2024 | 0.6725 |
| April 10, 2024 | 0.6498 |
| April 09, 2024 | 0.708 |
| April 08, 2024 | 0.6854 |
| April 05, 2024 | 0.708 |
| April 04, 2024 | 0.7598 |
| April 03, 2024 | 0.7759 |
| April 02, 2024 | 0.8083 |
| Date | Value |
|---|---|
| April 01, 2024 | 0.8891 |
| March 28, 2024 | 0.9343 |
| March 27, 2024 | 0.7856 |
| March 26, 2024 | 0.7727 |
| March 25, 2024 | 0.818 |
| March 22, 2024 | 0.8244 |
| March 21, 2024 | 0.8826 |
| March 20, 2024 | 0.8988 |
| March 19, 2024 | 0.8309 |
| March 18, 2024 | 0.8276 |
| March 15, 2024 | 0.6175 |
| March 14, 2024 | 0.9376 |
| March 13, 2024 | 1.901 |
| March 12, 2024 | 1.893 |
| March 11, 2024 | 1.919 |
| March 08, 2024 | 2.121 |
| March 07, 2024 | 2.160 |
| March 06, 2024 | 2.069 |
| March 05, 2024 | 2.004 |
| March 04, 2024 | 1.988 |
| March 01, 2024 | 1.988 |
| February 29, 2024 | 2.004 |
| February 28, 2024 | 2.053 |
| February 27, 2024 | 2.079 |
| February 26, 2024 | 2.066 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
0.4649
Minimum
Apr 30 2024
5.083
Maximum
Nov 08 2021
1.979
Average
1.918
Median
Price to Book Value Benchmarks
| Geron Corp | 6.604 |
| SELLAS Life Sciences Group Inc | -- |
| Elicio Therapeutics Inc | 8.088 |
| Vistagen Therapeutics Inc | 1.008 |
| ADMA Biologics Inc | 11.72 |
Price to Book Value Related Metrics
| PS Ratio | 142.51 |
| PEG Ratio | -0.0595 |
| Price | 1.59 |
| Earnings Yield | -118.9% |
| Market Cap | 47.15M |
| PEGY Ratio | -0.0595 |